NxGEN Vector Solutions is pleased to share a new Life Sciences Review Innovation Insights
article by our founder, Susan M. Faust, Ph.D.
In “An Open Letter to the Gene Therapy Community on CpG Content and AAV Vector
Safety,” Dr. Faust urges the gene therapy field to recognize CpG content across the entire AAV
vector genome as a critical and controllable factor affecting immune activation, therapeutic
durability, and patient safety.
The article calls for greater transparency, data-driven CpG reduction strategies, and informed
discussion among developers, regulators, investigators, patients, and families as the field works
toward safer and more durable gene therapies.
